Anticancer (IC50) and hemolytic activities (MHC) of peptides against cancer cells and human red blood cells.

aAnticancer activity (IC50) represents the concentration of peptides at which cell viability was inhibited by 50% in comparison with the untreated cells. The MTT assay was repeated in triplicate, and IC50 value was determined by averaging three repeated experiments.

bGM of the anticancer activity (IC50) for the four cancer cell lines.

cHemolytic activity (MHC) was determined using human red blood cells after incubation with peptides for 1 h. If no hemolytic activity was observed at 500 μM, a value of 1000 μM was used for calculating the therapeutic index.

dTherapeutic index = MHC/IC50. Larger values indicate greater anticancer specificity.

GM, geometric mean; MHC, minimal hemolytic concentration.

Anticancer (IC50) and hemolytic activities (MHC) of peptides against cancer cells and human red blood cells.